cell therapy
Elicera CEO: “One of the biggest milestones in our history”
Elicera Therapeutics has officially entered the clinic with the drug candidate ELC-301. The CAR T-cell therapy is being evaluated in the Phase I/IIa study in patients...
The CAR T revolution in the fight against cancer
CAR T-cell therapies have shown potential to transform...
Idogen strengthens the board with Jan Holgersson
Idogen strengthens the board with Professor Jan Holgersson as...
Norwegian doctors prepare for Idogen's study
Biotechnology company Idogen is in full swing with preparations...
Principal investigator on Idogen's clinical study with IDO 8
Idogen recently announced that they have received approval...
Rights issue to take Xintela to the next level
The biomedical company Xintela is active in cell therapy and oncology...
Idogen's CEO on the issue outcome and the impact of the Corona crisis
Idogen presented the outcome of a rights issue on Wednesday...
Idogen's CEO comments on the new cooperation agreement
Idogen's CEO Anders Karlsson visits BioStock's studio at...
FDA predicts strong boost for cell and gene therapies
The US Food and Drug Administration (FDA) predicts that the number of approved...
Xintela: »Interest in cell therapy is very high in Asia«
With a busy 2018 in the rearview mirror, Xintela has...
PHI aims for improved cancer diagnostics with EU research funding
Phase Holographic Imaging (PHI) is a Lunda-based company...
Shift in power in European industry body favors cell and gene therapy companies
Recently, European Biopharmaceutical Enterprises (EBE), an industry association with...